^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EGFR G719C + EGFR S768I

    i
    Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
    Entrez ID:
    1956
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    2years
    Distinction of Tumor Heterogeneity From Synchronous/Collision Tumors in Lung Biopsies Using Targeted Next-Generation Sequencing Panel: A Retrospective Study (CAP 2022)
    Our results demonstrate that molecular profiling on DNA obtained from separately microdissected foci in heterogeneous tumors can prove helpful in separating true tumor heterogeneity from synchronous/collision tumors. This separation could be of utmost clinical importance to guide appropriate treatment management.
    Retrospective data • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1)
    |
    KRAS mutation • EGFR mutation • KRAS G12A • EGFR S768I • KRAS G12 • EGFR G719C • EGFR G719C + EGFR S768I • NKX2-1 expression
    2years
    Distinction of Tumor Heterogeneity From Synchronous/Collision Tumors in Lung Biopsies Using Targeted Next-Generation Sequencing Panel: A Retrospective Study (CAP 2022)
    Our results demonstrate that molecular profiling on DNA obtained from separately microdissected foci in heterogeneous tumors can prove helpful in separating true tumor heterogeneity from synchronous/collision tumors. This separation could be of utmost clinical importance to guide appropriate treatment management.
    Retrospective data • Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • TTF1 (Transcription Termination Factor 1) • NKX2-1 (NK2 Homeobox 1)
    |
    KRAS mutation • EGFR mutation • KRAS G12A • EGFR S768I • KRAS G12 • EGFR G719C • EGFR G719C + EGFR S768I • NKX2-1 expression
    almost3years
    Early Utilization of Next-Generation Sequencing Identifies Pancreatic Mass as Metastatic Tumor Originating from an EGFR Mutated Lung Adenocarcinoma (IASLC-TTLC 2022)
    The patient was started on osimertinib therapy... This case highlights the importance of early sequencing in pancreatic tumors that appear to be the primary site of malignancy. The use of NGS early in the patient's clinical course not only changed the treatment strategy but also drastically altered the prognosis. While metastatic pancreatic adenocarcinoma has with a poor prognosis and survival rate, treatment of EGFR-mutated non-small cell lung cancer (NSCLC) with EGFR tyrosine kinase inhibitors is associated with high response rates.
    Next-generation sequencing
    |
    EGFR (Epidermal growth factor receptor) • NKX2-1 (NK2 Homeobox 1) • NAPSA (Napsin A Aspartic Peptidase)
    |
    EGFR mutation • EGFR exon 20 insertion • EGFR S768I • EGFR exon 18 mutation • EGFR G719C • EGFR G719C + EGFR S768I
    |
    Tagrisso (osimertinib)
    over3years
    Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations. (PubMed, Thorac Cancer)
    No abstract available
    Clinical • Journal
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR S768I • EGFR G719C • EGFR G719C + EGFR S768I
    |
    Gilotrif (afatinib)
    over4years
    [VIRTUAL] Hybrid capture-based assays in primary diagnostics of NSCLC patients: Results from the NEOlung study (ESMO 2020)
    Funding: Pfizer Pharma GmbH. Clinical trial identification: Study Number 2016/01.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1)
    |
    KRAS mutation • BRAF mutation • ROS1 fusion • EGFR S768I • EGFR G719C • EGFR mutation + KRAS mutation • EGFR G719C + EGFR S768I • ALK-ROS1 fusion • EGFR E746